Businessman with an umbrella is facing strong headwind


We beforehand mentioned Bristol-Myers Squibb Firm (NYSE:BMY) in September 2023, discussing its Loss Of Exclusivity concern with its main product, Revlimid, resulting in a big decline in annualized gross sales to $5.5B in 2023, in comparison with $12.82B in 2021.

Mixed with


Source link